Christopher Ocampo

2.7k total citations · 2 hit papers
33 papers, 2.2k citations indexed

About

Christopher Ocampo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Christopher Ocampo has authored 33 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Otorhinolaryngology. Recurrent topics in Christopher Ocampo's work include HER2/EGFR in Cancer Research (7 papers), Sinusitis and nasal conditions (6 papers) and Glioma Diagnosis and Treatment (5 papers). Christopher Ocampo is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Sinusitis and nasal conditions (6 papers) and Glioma Diagnosis and Treatment (5 papers). Christopher Ocampo collaborates with scholars based in United States, Japan and Netherlands. Christopher Ocampo's co-authors include Gilla Kaplan, Laura G. Corral, Patrick Haslett, George W. Muller, David Stirling, Lai Mun Wong, Roger Chen, Anju T. Peters, Howard S. Silverman and Michael D. Stern and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Christopher Ocampo

33 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

1999 635 citations Laura G. Corral, Patrick Haslett et al. PubMed profile →
Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α

1999 577 citations Laura G. Corral, Patrick Haslett et al. The Journal of Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Ocampo United States	17	929	862	578	349	342	33	2.2k
Wolfgang Oster Germany	28	674 0.7×	666 0.8×	760 1.3×	791 2.3×	199 0.6×	101	3.0k
Ludwig Wilkens Germany	27	1.2k 1.3×	401 0.5×	575 1.0×	240 0.7×	154 0.5×	77	2.5k
Mark Blick United States	28	1.0k 1.1×	830 1.0×	999 1.7×	343 1.0×	80 0.2×	55	2.8k
G Wong Canada	18	433 0.5×	671 0.8×	820 1.4×	578 1.7×	112 0.3×	22	2.0k
Jonathan H. Axelrod Israel	25	919 1.0×	172 0.2×	416 0.7×	259 0.7×	170 0.5×	45	2.2k
D J Tweardy United States	11	719 0.8×	176 0.2×	771 1.3×	470 1.3×	60 0.2×	11	1.8k
Hirotaka Matsui Japan	28	1.4k 1.5×	780 0.9×	368 0.6×	270 0.8×	80 0.2×	116	2.3k
Akira Kitanaka Japan	23	751 0.8×	348 0.4×	465 0.8×	392 1.1×	65 0.2×	80	1.7k
Laurence Panicot‐Dubois France	27	895 1.0×	772 0.9×	816 1.4×	633 1.8×	91 0.3×	70	2.7k
Anna Teresa Maiolo Italy	25	1.0k 1.1×	879 1.0×	499 0.9×	420 1.2×	86 0.3×	86	2.3k

Countries citing papers authored by Christopher Ocampo

Since Specialization

Citations

This map shows the geographic impact of Christopher Ocampo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Ocampo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Ocampo more than expected).

Fields of papers citing papers by Christopher Ocampo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Ocampo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Ocampo. The network helps show where Christopher Ocampo may publish in the future.

Co-authorship network of co-authors of Christopher Ocampo

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Ocampo. A scholar is included among the top collaborators of Christopher Ocampo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Ocampo. Christopher Ocampo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fujiwara, Yutaka, Hirotsugu Kenmotsu, Noboru Yamamoto, et al.. (2021). Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Cancer Medicine. 10(7). 2350–2358. 10 indexed citations

Camidge, D. Ross, Fedor Moiseenko, İrfan Çiçin, et al.. (2021). Abstract CT179: Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer. Cancer Research. 81(13_Supplement). CT179–CT179. 9 indexed citations

Camidge, D. Ross, Jonathan W. Goldman, George W. Cole, et al.. (2020). 1414TiP Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort. Annals of Oncology. 31. S894–S894. 4 indexed citations

Cleary, James M., Emiliano Calvo, Víctor Moreno, et al.. (2020). A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Investigational New Drugs. 38(5). 1483–1494. 24 indexed citations

Lassman, Andrew B., Kenneth Aldape, Peter Ansell, et al.. (2019). Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. Journal of Neuro-Oncology. 144(1). 205–210. 30 indexed citations

Bent, Martin J. van den, Lisa Roberts-Rapp, Peter Ansell, et al.. (2017). ACTR-13. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION RATES OBSERVED IN SCREENING PATIENTS FOR RANDOMIZED CLINICAL TRIALS IN GLIOBLASTOMA. Neuro-Oncology. 19(suppl_6). vi3–vi4. 1 indexed citations

Gottlieb, Alice B., Alan Menter, April W. Armstrong, et al.. (2016). Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.. PubMed. 15(10). 1192–1196. 16 indexed citations

Stevens, Whitney W., Christopher Ocampo, Sergejs Berdnikovs, et al.. (2015). Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease. American Journal of Respiratory and Critical Care Medicine. 192(6). 682–694. 222 indexed citations

Stevens, Whitney W., Christopher Ocampo, James E. Norton, et al.. (2015). Investigation of Molecular Characteristics of Aspirin Exacerbated Respiratory Disease. Journal of Allergy and Clinical Immunology. 135(2). AB170–AB170. 1 indexed citations

10.

Pothoven, Kathryn L., James Norton, Christopher Ocampo, et al.. (2014). Oncostatin M Is Elevated In Chronic Rhinosinusitis and Decreases Barrier Function In Human Airway Epithelium. Journal of Allergy and Clinical Immunology. 133(2). AB237–AB237. 4 indexed citations

11.

Ocampo, Christopher & Leslie C. Grammer. (2013). Chronic Rhinosinusitis. The Journal of Allergy and Clinical Immunology In Practice. 1(3). 205–211. 10 indexed citations

12.

Ocampo, Christopher & Anju T. Peters. (2013). Antibody Deficiency in Chronic Rhinosinusitis: Epidemiology and Burden of Illness. American Journal of Rhinology and Allergy. 27(1). 34–38. 51 indexed citations

13.

Griffiths, Elinor J., Christopher Ocampo, Joshua Savage, Michael D. Stern, & Howard S. Silverman. (2000). Protective effects of low and high doses of cyclosporin A against reoxygenation injury in isolated rat cardiomyocytes are associated with differential effects on mitochondrial calcium levels. Cell Calcium. 27(2). 87–95. 46 indexed citations

14.

Oliver, Stephen J., Sherry Freeman, Laura G. Corral, Christopher Ocampo, & Gilla Kaplan. (1999). Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clinical & Experimental Immunology. 118(2). 315–321. 26 indexed citations

15.

Corral, Laura G., Patrick Haslett, George W. Muller, et al.. (1999). Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α. The Journal of Immunology. 163(1). 380–386. 577 indexed citations breakdown →

16.

Zaragoza, Carlos, Christopher Ocampo, Marta Saura, et al.. (1999). Inducible Nitric Oxide Synthase Protection Against Coxsackievirus Pancreatitis. The Journal of Immunology. 163(10). 5497–5504. 49 indexed citations

17.

Corral, Laura G., Patrick Haslett, George W. Muller, et al.. (1999). Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.. PubMed. 163(1). 380–6. 635 indexed citations breakdown →

18.

Zaragoza, Carlos, Christopher Ocampo, Marta Saura, et al.. (1998). The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis. Proceedings of the National Academy of Sciences. 95(5). 2469–2474. 90 indexed citations

19.

Zaragoza, Carlos, Christopher Ocampo, Marta Saura, A McMillan, & Charles J. Lowenstein. (1997). Nitric oxide inhibition of coxsackievirus replication in vitro.. Journal of Clinical Investigation. 100(7). 1760–1767. 78 indexed citations

20.

Griffiths, Elinor J., Shao-kui Wei, Mark C. Haigney, et al.. (1997). Inhibition of mitochondrial calcium efflux by clonazepam in intact single rat cardiomyocytes and effects on NADH production. Cell Calcium. 21(4). 321–329. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact